Wanbury Limited has informed the Exchange regarding a press release dated March 12, 2026, titled "Press Release dated 12.03.2026".
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wanbury Limited has received Form II approval from ANVISA (Brazil's health regulator) for Sertraline, in addition to its existing Form I approval. The company already holds about 75% market share for Sertraline in Brazil, and the new approval is expected to help further consolidate its position. Separately, Wanbury has received approval from one of its largest customers for a special grade of Metformin (DC grade), representing a potential business opportunity of around Rs. 15 crore per annum. Both of the company's API manufacturing facilities at Patalganga and Tanuku continue to comply with cGMP standards.
Positive for shareholders — the Brazil approval strengthens Wanbury's dominant position in a key export market, while the new Metformin approval opens an estimated Rs. 15 crore annual revenue opportunity from a major customer, supporting future earnings growth.